Non-insulin antidiabetics – Incretin mimetics – leaders in a diverse pipeline

Datamonitor expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.

Incretin mimetics, GLP-1 agonists and DPP-IV inhibitors, are likely to be the most successful candidates in the pipeline. Pipeline incretin candidates are forecast to generate sales of $7,905m in the seven major markets in 2017.

A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 137 candidates from 60 different mechanisms of action are in development.

Big Pharma dominate the non-insulin antidiabetic pipeline as the disease is one of the few growth areas in the cardiovascular and metabolic disease areas. Sixteen of the top twenty drug companies have a non-insulin antidiabetic pipeline and between them are developing 52% of the pipeline.

Read more...

• Obesity Drug Markets (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)

• Insulin antidiabetics (09/10/2008)
• Multiple Sclerosis (07/10/2008)

• Biosimilars-Regulatory Issues (27/05/2008)
• Hematological Malignancies (21/05/2008)
• Biosimilars regulatory and development issues (20/05/2008)
• Monoclonal Antibodies Report Part II (19/05/2008)
• Acute Stroke (19/05/2008)
• Antifungals (16/05/2008)
• NNRTIs (16/05/2008)
• Non-Hodgkin's Lymphoma (16/05/2008)
• Multiple Myeloma (16/05/2008)

---